



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/785,414		02/25/2004	Juergen Roemisch	06478.1447-01	8362	
22852	7590	08/22/2005		EXAMINER		
	N, HEND	DERSON, FARAB	SZPERKA, MICHAEL EDWARD			
LLP 901 NEW Y	ORK AV	ENUE, NW		ART UNIT	PAPER NUMBER	
WASHING	ron, dc	20001-4413		1644		

DATE MAILED: 08/22/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	<u> </u>
	10/785,414	ROEMISCH ET AL.	7
Office Action Summary	Examiner	Art Unit	
	Michael Szperka	1644	•
The MAILING DATE of this communication a	•	vith the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a r - If NO period for reply is specified above, the maximum statutory perion - Failure to reply within the set or extended period for reply will, by state and yreply received by the Office later than three months after the may be a searned patent term adjustment. See 37 CFR 1.704(b). Status	N. 1.136(a). In no event, however, may a reply within the statutory minimum of the dod will apply and will expire SIX (6) MC tute, cause the application to become A	a reply be timely filed iirty (30) days will be considered timely. DNTHS from the mailing date of this communicati ABANDONED (35 U.S.C. § 133).	ion.
1) Responsive to communication(s) filed on 25	5 February 2004.		
2a) ☐ This action is FINAL . 2b) ☑ This action is FINAL . 2b) ☑ This action is incondition for allow	his action is non-final.	tters prosecution as to the merits	ie
closed in accordance with the practice unde	•	• •	
Disposition of Claims			
4) ☑ Claim(s) 9-29 is/are pending in the application 4a) Of the above claim(s) is/are withd 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☑ Claim(s) 9-29 are subject to restriction and/or	Irawn from consideration.		-
Application Papers			
9) The specification is objected to by the Exami			
10) The drawing(s) filed on is/are: a) a		•	•
Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction. 11) The oath or declaration is objected to by the	rection is required if the drawin	g(s) is objected to. See 37 CFR 1.121	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for forei a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a li	ents have been received. ents have been received in riority documents have bee eau (PCT Rule 17.2(a)).	Application No n received in this National Stage	·
Attachment(s)			
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/C Paper No(s)/Mail Date 	Paper No	Summary (PTO-413) o(s)/Mail Date Informal Patent Application (PTO-152)	ļ

HL

Application/Control Number: 10/785,414 Page 2

Art Unit: 1644

DETAILED ACTION

1. Applicant's preliminary amendment received February 25, 2004 is acknowledged.

Claims 1-8 have been cancelled.

Claims 9-29 have been added and are pending in the instant application.

Election/Restrictions

This application contains claims directed to the following patentably distinct species of the claimed invention: The species are the identity of the disease or disorder being treated by Applicant's claimed method. Applicant is required to elect a single, defined disease or disorder in response to this election requirement. Examples of specific diseases and disorders recited in the claims are systemic lupus erythematosus, urticaria, and Alzheimer's disease. Note that election of a generic disease or disorder, such as autoimmune disease, allergy, or neurodegenerative disease would not be considered to be fully responsive since these are genus terms that read on more than one specific disease or condition. These species are distinct because they differ in their etiology, clinical manifestations, progression, standard courses of treatment, patient prognosis, and therapeutic endpoints and outcomes.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 9-13, 15-19, 21-23, and 26-29 generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 10/785,414 Page 4

Art Unit: 1644

2. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- 3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is 571-272-2934. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/785,414 Page 5

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael Szperka, Ph.D. Patent Examiner Technology Center 1600 August 9, 2005 Patrick J. Nolan, Ph.D. Primary Examiner Technology Center 1600